• レポートコード:D005-00709 • 出版社/出版日:GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態:英文、PDF、108ページ • 納品方法:Eメール • 産業分類:医療・製薬 |
Single User | ¥522,000 (USD3,480) | ▷ お問い合わせ |
Multi User | ¥783,000 (USD5,220) | ▷ お問い合わせ |
Corporate User | ¥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、多発性骨髄腫治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。多発性骨髄腫治療の種類別市場規模(プロテアソーム阻害剤、免疫調節剤(IMiD)、ヒストン脱アセチル化酵素(HDAC)阻害剤、免疫療法、細胞毒性化学療法)、用途別市場規模(病院、クリニック、がん治療・リハビリセンター)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報(販売量、市場シェア、製品概要、SWOT分析):Johnson & Johnson、Eli Lilly、Roche Holding、Sanofi、Novartis ・地域別グローバル市場分析 2015年-2020年 ・多発性骨髄腫治療の北米市場(アメリカ、カナダ、メキシコ) ・多発性骨髄腫治療のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア) ・多発性骨髄腫治療のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア) ・多発性骨髄腫治療の南米市場(ブラジル、アルゼンチン) ・多発性骨髄腫治療の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ) ・種類別分析:プロテアソーム阻害剤、免疫調節剤(IMiD)、ヒストン脱アセチル化酵素(HDAC)阻害剤、免疫療法、細胞毒性化学療法 ・用途別分析:病院、クリニック、がん治療・リハビリセンター ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Multiple Myeloma Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 10.2% in the forecast period of 2020 to 2025 and will expected to reach USD 41350 million by 2025, from USD 28060 million in 2019.
The Multiple Myeloma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Multiple Myeloma Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Multiple Myeloma Treatment market has been segmented into:
Proteasome Inhibitors
Immunomodulatory Agents (IMiDs)
Histone Deacetylase (HDAC) Inhibitors
Immunotherapy
Cytotoxic Chemotherapy
By Application, Multiple Myeloma Treatment has been segmented into:
Hospitals
Clinics
Cancer Treatment and Rehabilitation Centers
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Multiple Myeloma Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Multiple Myeloma Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Multiple Myeloma Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Multiple Myeloma Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Multiple Myeloma Treatment Market Share Analysis
Multiple Myeloma Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Multiple Myeloma Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Multiple Myeloma Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Multiple Myeloma Treatment are:
Johnson & Johnson
Eli Lilly
Roche Holding
Sanofi
Novartis
Table of Contents
1 Multiple Myeloma Treatment Market Overview
1.1 Product Overview and Scope of Multiple Myeloma Treatment
1.2 Classification of Multiple Myeloma Treatment by Type
1.2.1 Global Multiple Myeloma Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Multiple Myeloma Treatment Revenue Market Share by Type in 2019
1.2.3 Proteasome Inhibitors
1.2.4 Immunomodulatory Agents (IMiDs)
1.2.5 Histone Deacetylase (HDAC) Inhibitors
1.2.6 Immunotherapy
1.2.7 Cytotoxic Chemotherapy
1.3 Global Multiple Myeloma Treatment Market by Application
1.3.1 Overview: Global Multiple Myeloma Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Cancer Treatment and Rehabilitation Centers
1.4 Global Multiple Myeloma Treatment Market by Regions
1.4.1 Global Multiple Myeloma Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Multiple Myeloma Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Multiple Myeloma Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Multiple Myeloma Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Multiple Myeloma Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Multiple Myeloma Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Multiple Myeloma Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Johnson & Johnson SWOT Analysis
2.1.4 Johnson & Johnson Product and Services
2.1.5 Johnson & Johnson Multiple Myeloma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Eli Lilly SWOT Analysis
2.2.4 Eli Lilly Product and Services
2.2.5 Eli Lilly Multiple Myeloma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Roche Holding
2.3.1 Roche Holding Details
2.3.2 Roche Holding Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Roche Holding SWOT Analysis
2.3.4 Roche Holding Product and Services
2.3.5 Roche Holding Multiple Myeloma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Sanofi SWOT Analysis
2.4.4 Sanofi Product and Services
2.4.5 Sanofi Multiple Myeloma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Novartis SWOT Analysis
2.5.4 Novartis Product and Services
2.5.5 Novartis Multiple Myeloma Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Multiple Myeloma Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Multiple Myeloma Treatment Players Market Share
3.2.2 Top 10 Multiple Myeloma Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Multiple Myeloma Treatment Revenue and Market Share by Regions
4.2 North America Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
5 North America Multiple Myeloma Treatment Revenue by Countries
5.1 North America Multiple Myeloma Treatment Revenue by Countries (2015-2020)
5.2 USA Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
6 Europe Multiple Myeloma Treatment Revenue by Countries
6.1 Europe Multiple Myeloma Treatment Revenue by Countries (2015-2020)
6.2 Germany Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
6.4 France Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Multiple Myeloma Treatment Revenue by Countries
7.1 Asia-Pacific Multiple Myeloma Treatment Revenue by Countries (2015-2020)
7.2 China Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
7.5 India Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
8 South America Multiple Myeloma Treatment Revenue by Countries
8.1 South America Multiple Myeloma Treatment Revenue by Countries (2015-2020)
8.2 Brazil Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Multiple Myeloma Treatment by Countries
9.1 Middle East & Africa Multiple Myeloma Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Multiple Myeloma Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Multiple Myeloma Treatment Market Forecast by Type (2019-2024)
10.3 Proteasome Inhibitors Revenue Growth Rate (2015-2025)
10.4 Immunomodulatory Agents (IMiDs) Revenue Growth Rate (2015-2025)
10.5 Histone Deacetylase (HDAC) Inhibitors Revenue Growth Rate (2015-2025)
10.6 Immunotherapy Revenue Growth Rate (2015-2025)
10.7 Cytotoxic Chemotherapy Revenue Growth Rate (2015-2025)
11 Global Multiple Myeloma Treatment Market Segment by Application
11.1 Global Multiple Myeloma Treatment Revenue Market Share by Application (2015-2020)
11.2 Multiple Myeloma Treatment Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Cancer Treatment and Rehabilitation Centers Revenue Growth (2015-2020)
12 Global Multiple Myeloma Treatment Market Size Forecast (2021-2025)
12.1 Global Multiple Myeloma Treatment Market Size Forecast (2021-2025)
12.2 Global Multiple Myeloma Treatment Market Forecast by Regions (2021-2025)
12.3 North America Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
12.6 South America Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Multiple Myeloma Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Multiple Myeloma Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Multiple Myeloma Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Multiple Myeloma Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Johnson & Johnson Corporate Information, Location and Competitors
Table 6. Johnson & Johnson Multiple Myeloma Treatment Major Business
Table 7. Johnson & Johnson Multiple Myeloma Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Johnson & Johnson SWOT Analysis
Table 9. Johnson & Johnson Multiple Myeloma Treatment Product and Solutions
Table 10. Johnson & Johnson Multiple Myeloma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Eli Lilly Corporate Information, Location and Competitors
Table 12. Eli Lilly Multiple Myeloma Treatment Major Business
Table 13. Eli Lilly Multiple Myeloma Treatment Total Revenue (USD Million) (2018-2019)
Table 14. Eli Lilly SWOT Analysis
Table 15. Eli Lilly Multiple Myeloma Treatment Product and Solutions
Table 16. Eli Lilly Multiple Myeloma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Roche Holding Corporate Information, Location and Competitors
Table 18. Roche Holding Multiple Myeloma Treatment Major Business
Table 19. Roche Holding Multiple Myeloma Treatment Total Revenue (USD Million) (2017-2018)
Table 20. Roche Holding SWOT Analysis
Table 21. Roche Holding Multiple Myeloma Treatment Product and Solutions
Table 22. Roche Holding Multiple Myeloma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Sanofi Corporate Information, Location and Competitors
Table 24. Sanofi Multiple Myeloma Treatment Major Business
Table 25. Sanofi Multiple Myeloma Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Sanofi SWOT Analysis
Table 27. Sanofi Multiple Myeloma Treatment Product and Solutions
Table 28. Sanofi Multiple Myeloma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Novartis Corporate Information, Location and Competitors
Table 30. Novartis Multiple Myeloma Treatment Major Business
Table 31. Novartis Multiple Myeloma Treatment Total Revenue (USD Million) (2017-2018)
Table 32. Novartis SWOT Analysis
Table 33. Novartis Multiple Myeloma Treatment Product and Solutions
Table 34. Novartis Multiple Myeloma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Global Multiple Myeloma Treatment Revenue (Million USD) by Players (2015-2020)
Table 36. Global Multiple Myeloma Treatment Revenue Share by Players (2015-2020)
Table 37. Global Multiple Myeloma Treatment Revenue (Million USD) by Regions (2015-2020)
Table 38. Global Multiple Myeloma Treatment Revenue Market Share by Regions (2015-2020)
Table 39. North America Multiple Myeloma Treatment Revenue by Countries (2015-2020)
Table 40. North America Multiple Myeloma Treatment Revenue Market Share by Countries (2015-2020)
Table 41. Europe Multiple Myeloma Treatment Revenue (Million USD) by Countries (2015-2020)
Table 42. Asia-Pacific Multiple Myeloma Treatment Revenue (Million USD) by Countries (2015-2020)
Table 43. South America Multiple Myeloma Treatment Revenue by Countries (2015-2020)
Table 44. South America Multiple Myeloma Treatment Revenue Market Share by Countries (2015-2020)
Table 45. Middle East and Africa Multiple Myeloma Treatment Revenue (Million USD) by Countries (2015-2020)
Table 46. Middle East and Africa Multiple Myeloma Treatment Revenue Market Share by Countries (2015-2020)
Table 47. Global Multiple Myeloma Treatment Revenue (Million USD) by Type (2015-2020)
Table 48. Global Multiple Myeloma Treatment Revenue Share by Type (2015-2020)
Table 49. Global Multiple Myeloma Treatment Revenue Forecast by Type (2021-2025)
Table 50. Global Multiple Myeloma Treatment Revenue by Application (2015-2020)
Table 51. Global Multiple Myeloma Treatment Revenue Share by Application (2015-2020)
Table 52. Global Multiple Myeloma Treatment Revenue Forecast by Application (2021-2025)
Table 53. Global Multiple Myeloma Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Multiple Myeloma Treatment Picture
Figure 2. Global Multiple Myeloma Treatment Revenue Market Share by Type in 2019
Figure 3. Proteasome Inhibitors Picture
Figure 4. Immunomodulatory Agents (IMiDs) Picture
Figure 5. Histone Deacetylase (HDAC) Inhibitors Picture
Figure 6. Immunotherapy Picture
Figure 7. Cytotoxic Chemotherapy Picture
Figure 8. Multiple Myeloma Treatment Revenue Market Share by Application in 2019
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Cancer Treatment and Rehabilitation Centers Picture
Figure 12. Global Multiple Myeloma Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Multiple Myeloma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Multiple Myeloma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Multiple Myeloma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Multiple Myeloma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Multiple Myeloma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Multiple Myeloma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Multiple Myeloma Treatment Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Multiple Myeloma Treatment Revenue Market Share in 2019
Figure 21. Global Top 10 Players Multiple Myeloma Treatment Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Multiple Myeloma Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Multiple Myeloma Treatment Revenue Market Share by Regions (2015-2020)
Figure 25. Global Multiple Myeloma Treatment Revenue Market Share by Regions in 2018
Figure 26. North America Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 27. Europe Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 29. South America Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 31. North America Multiple Myeloma Treatment Revenue Market Share by Countries (2015-2020)
Figure 32. North America Multiple Myeloma Treatment Revenue Market Share by Countries in 2019
Figure 33. USA Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Canada Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 36. Europe Multiple Myeloma Treatment Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Multiple Myeloma Treatment Revenue Market Share by Countries in 2019
Figure 38. Germany Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 39. UK Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 40. France Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Russia Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 42. Italy Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Multiple Myeloma Treatment Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Multiple Myeloma Treatment Revenue Market Share by Countries in 2019
Figure 45. China Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Japan Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 47. Korea Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 48. India Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 50. South America Multiple Myeloma Treatment Revenue Market Share by Countries (2015-2020)
Figure 51. South America Multiple Myeloma Treatment Revenue Market Share by Countries in 2019
Figure 52. Brazil Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Multiple Myeloma Treatment Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Multiple Myeloma Treatment Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 57. UAE Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Multiple Myeloma Treatment Revenue and Growth Rate (2015-2020)
Figure 60. Global Multiple Myeloma Treatment Revenue Share by Type (2015-2020)
Figure 61. Global Multiple Myeloma Treatment Revenue Share by Type in 2019
Figure 62. Global Multiple Myeloma Treatment Market Share Forecast by Type (2021-2025)
Figure 63. Global Proteasome Inhibitors Revenue Growth Rate (2015-2020)
Figure 64. Global Immunomodulatory Agents (IMiDs) Revenue Growth Rate (2015-2020)
Figure 65. Global Histone Deacetylase (HDAC) Inhibitors Revenue Growth Rate (2015-2020)
Figure 66. Global Immunotherapy Revenue Growth Rate (2015-2020)
Figure 67. Global Cytotoxic Chemotherapy Revenue Growth Rate (2015-2020)
Figure 68. Global Multiple Myeloma Treatment Revenue Share by Application (2015-2020)
Figure 69. Global Multiple Myeloma Treatment Revenue Share by Application in 2019
Figure 70. Global Multiple Myeloma Treatment Market Share Forecast by Application (2021-2025)
Figure 71. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 72. Global Clinics Revenue Growth Rate (2015-2020)
Figure 73. Global Cancer Treatment and Rehabilitation Centers Revenue Growth Rate (2015-2020)
Figure 74. Global Multiple Myeloma Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Multiple Myeloma Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Multiple Myeloma Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
Figure 78. Europe Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
Figure 80. South America Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Multiple Myeloma Treatment Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel